Gain Therapeutics, Inc. (GANX) Form 8-K — Sep 28, 2026

$GANXForm 8-KItems 5.02Filed Sep 28, 2026, 4:30 PM ET0001104659-26-111391Original filing

Gain Therapeutics' principal financial officer Gianluca Fuggetta resigned effective September 30, 2026, to pursue other opportunities. CEO Gene Mack was appointed interim CFO effective October 1, 2026, keeping his President and CEO roles while assuming principal financial and accounting officer duties.

Key figures

Cfo effective date: 2026-09-30
Interim cfo effective date: 2026-10-01

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.